| Keywords: |
adult; leukemia; human cell; review; dose response; drug efficacy; drug potentiation; t lymphocyte; t-lymphocytes; animal cell; mouse; animal; heredity; interleukin 2; spleen; age factors; in vitro study; drug screening; age; drug receptor binding; lymphocyte activation; immune tolerance; antibodies, monoclonal; gamma interferon; drug accumulation; drug mechanism; genetic engineering; infant, newborn; diagnosis; drug response; rat; newborn; burn; killer cells, natural; acquired immune deficiency syndrome; acquired immunodeficiency syndrome; radioisotope; immune deficiency; cyclosporin a; bone marrow transplantation; drug determination; growth factor; molecular weight; drug tolerance; immunologic deficiency syndromes; therapy; drug isolation; clinical trials; injury; pharmacokinetics; interleukin-2; receptors, immunologic; hemophilia; hemophilia a; thymidine h 3; etiology; drug purification; interleukin 2 receptor; receptors, interleukin-2; drug comparison; burns; phytohemagglutinin; okt 3; cancer; human; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; congenital disorder; blood and hemopoietic system; drug analysis
|
